Publication | Open Access
Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
23
Citations
8
References
2020
Year
Clinical ImmunologyCd33+cd11b+hla-dr–cd14+cd66b– CellsCd11b+cd33+hla-dr-cd14+ CellsViral DiagnosticsAdaptive Immune SystemImmunodeficienciesImmunologyImmune RegulationImmunodominancePeripheral BloodCd4 T Cell ResponsesCommon Clinical FeaturesCovid-19 EpidemiologyImmune SystemImmune DysregulationCovid-19Severity Immune BiomarkersRespiratory InfectionCovid-19 SeverityCovid-19 PandemicVirologyImmune SurveillanceHumoral ImmunityT Cell ImmunityImmune FunctionChronic Viral InfectionSystems ImmunologyInfectious Respiratory DiseaseMedicineImmunological Biomarkers
Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.
| Year | Citations | |
|---|---|---|
Page 1
Page 1